Sartobind® Rapid A: A Scalable, Disposable, Ready-To-Use mAb Capture Membrane
Replace Columns With A Scalable, Ready-To-Use & Disposable Alternative
Resin-based packed bed chromatography for mAb capture hampers downstream processing with low productivity, laborious cleaning requirements, and high costs. Sartobind® Rapid A is a game-changing, disposable "plug and play" alternative that uses a one-batch, one-membrane approach through rapid cycling. Its advantages over resin-based batch operations include:
- 10x increased productivity
- Reduced bioburden risk
- Lower CoGs
- Fully proven scalable solution from PD to commercial scale
Sartobind® Rapid A - Plug and Play mAb Capture
Traditional mAb capture methods are inefficient and costly. Sartobind® Rapid A from Sartorius changes the game with a one-batch, one-membrane alternative that cuts time, risks, and costs associated with resin-based batch operations.
Want to Remove the mAb Capture Bottleneck?
See first-hand how Sartobind® Rapid A delivers a tenfold increase in productivity with Sartorius’ new chromatography membrane. Learn more about the product’s scalability, from PD to commercial, and how to remove the mAb capture bottleneck.
No more column handling or risky consumable reuse — Sartobind® Rapid A removes the need for resin.
Sartobind® Rapid A cuts costs using less chromatographic material per batch which will be fully utilized.
Rapid cycling and high binding capacity boost productivity 10x. Perform lifetime studies in one day.
Scale up based on binding capacity with constant residence time, productivity, and operating pressures.
Using a new membrane for each batch eliminates the risk of bioburden.
Scale Up Faster With Zero Columns
Adopt a Fully Proven Scalable Solution From PD to Commercial Scale
Sartobind® Rapid A is the first portfolio to cover PD, clinical and commercial scales. A constant bed height over different device sizes allows easy scale-up based on binding capacity, preserving productivity, flow rates, and quality.
- Scale up seamlessly
- Simplify linear scalability with modular cassette format
- Benefit from short cycle times, high productivity, and operating pressures <0.2 MPa
Scale Up Easily With the Sartobind® Rapid A Portfolio
Sartobind® Rapid A is a fully proven scalable solution from PD to commercial scale. Devices include nano- and mini-sized solutions for benchtop systems, larger capsules for pilot testing, and modular cassettes for commercial manufacturing. The family of products eases the gradual expansion of rapid cycle chromatography across your operations.
- Ligand: Protein A
- Bed height: 4 mm
Attributes | Sartobind® Rapid A Nano | Sartobind® Rapid A Mini | Sartobind® Rapid A 75 mL | Sartobind® Rapid A 200 mL | Sartobind® Rapid A Cassette |
|---|---|---|---|---|---|
Scale of Operation | Process Development | Process Development | Clinical Scale | Clinical Scale | Late Clinical to Commercial Scale |
Membrane Volume | 1.2 mL | 10 mL | 75 mL | 200 mL | 800 mL |
Connector | Female luer | Female luer; sanitary ¾”, 25 mm | Sanitary ¾”, 25 mm | Sanitary 1 ½”, 50.5 mm | Via manifold accessory: sanitary 1 ½”, 50.5 mm |
| View Products | View Products | View Products | View Products |
Save Time, Cut Costs and Reduce Risk With Sartobind® Rapid A
Rapid Cycling Yields Higher Productivity at Lower Cost With Less Risk
Sartobind® Rapid A’s one-batch, one-membrane approach minimizes bioburden risks, cuts unproductive activities, and saves on developing therapeutics by removing the high cost of bulk resin. Sartobind® Rapid A represents the next generation of mAb capture.
- Cut 80% of non-productive column-use activities
- Save up to 30% on process costs in clinical scale production
- Minimize cross-contamination risk
Traditional Batch vs. Rapid Cycling Chromatography
Break Through DSP Bottlenecks With Sartobind® Rapid A
Process intensification efforts on the upstream side have contributed to bottlenecks downstream. Typical batch approaches to mAb capture can lengthen process times. To break through this bottleneck in downstream processing, Sartorius developed a new technology. Rapid cycling chromatography with Sartobind® Rapid A improves productivity to accelerate speed to clinic.
Rapid Cycling Chromatography
Rapid cycling chromatography purifies a batch over a large number of very short cycles. To make this possible, a new matrix was developed that allows comparable binding capacity at shorter residence time (higher flow rates).
- One small device for mAb capture
- One batch is purified over a large number of cycles
- 10-15 minute cycles
- Typical productivity of the mAb capture step: > 150 g/L*h
Packed Bed Chromatography in Batch Approach
Packed bed chromatography in batch mode is often used to purify mAbs. One unit operation is completed at a time. A volume of mAbs is purified over a set number of cycles in a large column with a packed bed of protein A resin. The eluate from each batch is combined before virus inactivation.
- 3-6 cycles per batch
- Complete a single cycle in 2-4 hours
- Protein A resin productivity: 10 – 20 g/L*h
Chromatography System Solutions Ideally Suited for Sartobind® Rapid A
Learn More About Rapid A Chromatography
The Next Generation of Chromatography
Conventional chromatographic matrices include, among others, resins and membranes. Mass transport in resins relies on diffusion, while in membranes, it uses convection. Both have drawbacks. Mass diffuses slowly through resins, causing low productivity. Membrane structures force users to accept a tradeoff of inversely related production factors. However, a new generation of chromatographic materials combines the structure of resins with the convection of membranes. This ensures productivity, robustness, scalability, and easy cleaning.
Science Snippets Blog
Featured Assets
Frequently Asked Questions
Protein A chromatography is the most efficient stable affinity chromatography technique to concentrate and purify antibodies or Fc containing proteins in batch or continuous mode.
It is a proteinic ligand providing highly specific interaction with an antibody. It binds under mild conditions and elutes at lower pH enabling the removal of many product/process-related impurities.
It is a recombinant protein produced from mammalian cells (Chinese Hamster Ovary). It is secreted in the cell culture supernatant under perfusion or fed-batch conditions with titers up to 10 g/L.
It is a technique based on very high frequency of cycling of a quasi-flow rate independent chromatography consumable allowing much higher productivity and enabling a single-batch strategy.
